Partner Fund Management L.P. Has $64.41 Million Position in Audentes Therapeutics Inc (BOLD)

Partner Fund Management L.P. boosted its position in Audentes Therapeutics Inc (NASDAQ:BOLD) by 94.4% in the 4th quarter, Holdings Channel reports. The firm owned 3,021,259 shares of the biotechnology company’s stock after purchasing an additional 1,467,120 shares during the period. Audentes Therapeutics makes up about 1.7% of Partner Fund Management L.P.’s holdings, making the stock its 25th largest holding. Partner Fund Management L.P. owned 0.07% of Audentes Therapeutics worth $64,413,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Audentes Therapeutics by 15.8% during the 4th quarter. BlackRock Inc. now owns 2,974,591 shares of the biotechnology company’s stock valued at $63,418,000 after acquiring an additional 406,605 shares during the last quarter. Redmile Group LLC increased its stake in shares of Audentes Therapeutics by 0.7% during the 3rd quarter. Redmile Group LLC now owns 2,243,356 shares of the biotechnology company’s stock valued at $88,814,000 after acquiring an additional 14,700 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Audentes Therapeutics by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,342,931 shares of the biotechnology company’s stock valued at $53,166,000 after acquiring an additional 24,585 shares during the last quarter. Vanguard Group Inc increased its stake in shares of Audentes Therapeutics by 1.9% during the 3rd quarter. Vanguard Group Inc now owns 1,342,931 shares of the biotechnology company’s stock valued at $53,166,000 after acquiring an additional 24,585 shares during the last quarter. Finally, Jennison Associates LLC increased its stake in shares of Audentes Therapeutics by 0.8% during the 3rd quarter. Jennison Associates LLC now owns 1,028,668 shares of the biotechnology company’s stock valued at $40,725,000 after acquiring an additional 8,112 shares during the last quarter.

A number of research analysts have recently commented on BOLD shares. JPMorgan Chase & Co. started coverage on shares of Audentes Therapeutics in a research note on Monday, November 26th. They set an “overweight” rating and a $35.00 price objective for the company. Citigroup dropped their target price on shares of Audentes Therapeutics from $40.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 10th. BidaskClub raised shares of Audentes Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 5th. Zacks Investment Research raised shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research report on Tuesday, January 8th. Finally, Guggenheim raised shares of Audentes Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 target price for the company in a research report on Friday, January 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $34.49.

In other Audentes Therapeutics news, VP Suyash Prasad sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $30.06, for a total value of $300,600.00. Following the completion of the transaction, the vice president now owns 28,236 shares in the company, valued at approximately $848,774.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Louis G. Lange sold 32,000 shares of the company’s stock in a transaction that occurred on Monday, December 24th. The stock was sold at an average price of $18.62, for a total value of $595,840.00. Following the completion of the transaction, the director now owns 325,799 shares of the company’s stock, valued at approximately $6,066,377.38. The disclosure for this sale can be found here. In the last 90 days, insiders sold 63,000 shares of company stock valued at $1,526,440. 6.60% of the stock is owned by company insiders.

NASDAQ BOLD traded up $0.83 on Monday, reaching $39.02. The company had a trading volume of 133,263 shares, compared to its average volume of 527,693. The stock has a market cap of $1.52 billion, a PE ratio of -11.48 and a beta of 1.90. Audentes Therapeutics Inc has a 1 year low of $17.95 and a 1 year high of $46.18.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.84) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.91) by $0.07. During the same period in the previous year, the firm posted ($0.82) earnings per share. Equities analysts anticipate that Audentes Therapeutics Inc will post -3.85 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Partner Fund Management L.P. Has $64.41 Million Position in Audentes Therapeutics Inc (BOLD)” was published by WKRB News and is the property of of WKRB News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.wkrb13.com/2019/03/18/partner-fund-management-l-p-has-64-41-million-position-in-audentes-therapeutics-inc-bold.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Recommended Story: Trading Strategy Examples and Plans

Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics Inc (NASDAQ:BOLD).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.